Why Receptos (RCPT) Stock Soared Today

NEW YORK (TheStreet) -- Receptos (RCPT) shares exploded in market trading on Tuesday, climbing 36.7% to $39.94, after reporting positive results from the phase 2 study of its oral relapsing multiple sclerosis treatment RPC1063.

The trial met its primary endpoint of reducing the number of MRI detected number of total gadolinium-enhancing lesions from the 12th week - 24th week of treatment.

An estimated 2 million people suffer from multiple sclerosis with more than half of them residing in the United States and Europe.

Must ReadWarren Buffett's 25 Favorite Stocks 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

RCPT Chart

RCPT data by YCharts


STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Video: Jim Cramer Reveals Why Stocks Are Moving Lower Thursday

Video: Jim Cramer Reveals Why Stocks Are Moving Lower Thursday

Dow Falls, S&P 500 Lower as Amazon Rises, Apple and P&G Slump

Dow Falls, S&P 500 Lower as Amazon Rises, Apple and P&G Slump

Soaring Nickel Prices Could Be Bad News for Electric Carmakers Like Tesla

Soaring Nickel Prices Could Be Bad News for Electric Carmakers Like Tesla

Video: The Road to S&P 500 2,800 Is 'Slow and Choppy'

Video: The Road to S&P 500 2,800 Is 'Slow and Choppy'

Let the Najarian Brothers Help You Generate Income With Options

Let the Najarian Brothers Help You Generate Income With Options